ArticleFrontiers in cardiovascular medicine2025
Mortality and trends of pulmonary arterial hypertension, 1990-2021: a population-based study.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary arterial hypertension (PAH) is a progressive disease associated with high fatality rate. Comprehensive evidence concerning the epidemiology of PAH mortality is lacking. The present study aimed to assess the mortality and trends of PAH at global, regional, and national levels from 1990 to 2021. Methods: The estimates and their 95% uncertainty interval for case number of PAH were collected from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2021. Age standardization by direct method was used to estimate the age-standardized mortality rate (ASMR) for PAH. We investigated the temporal trends of estimated ASMR from 1990 to 2021 and further predicted its changes in the next 15 years, decomposed the trends based on demographic factors and epidemiological changes, and quantified the cross-country health inequalities. Results: The global ASMR of PAH decreased from 0.35 (per 100,000 population) in 1990 to 0.27 (per 100,000 population) in 2021, with an annual percentage change of -0.82, while number of deaths increased from 14,842 in 1990 to 22,021 in 2021, an increase of 48.37%. Population growth and aging were the major drivers contributing to the number of deaths, accounting for 93.88% and 32.26%. Of note, there were significant health inequalities across 204 countries and territories, with the slope index of inequality rising over time. Projection of the global burden of PAH from 2022 to 2036 demonstrated a progressive increase in case number, but the ASMR remained largely unchanged. Conclusion: PAH remains a major public health concern in some regions, particularly in high sociodemographic index region. Adequate diagnosis and targeted treatment of PAH are urgently needed to achieve a reduction in mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.